Brexucabtagene Autoleucel – data collection during use for the indication of mantle cell lymphoma

22.08.2023 17:04

The application-accompanying data collection (AbD) for brexucabtagene autoleucel in the area of use of relapsed and refractory mantle cell lymphoma began as planned on August 21, 2023. From the point of view of the Federal Joint Committee (G-BA), the AbD in the form of a comparative registry study is necessary in order to demonstrate the additional benefit of the To be able to better assess CAR T-cell therapeutics in five years at the latest.

With the start of AbD, brexucabtagene autoleucel may only be used in the treatment of mantle cell lymphoma by doctors who document their data in the EMCL registry (Registry of the European Mantle Cell Lymphoma Network). Due to the very small patient group, all treatments should be recorded in the registry study if possible.

Doctors can find further information on the G-BA website:

Data collection accompanying use of brexucabtagene autoleucel

Brexucabtagene autoleucel in mantle cell lymphoma

Brexucabtagene autoleucel (Tecartus®) can be used in the treatment of mantle cell lymphoma in Germany since January 2021. It is approved as an orphan drug. The CAR T-cell therapeutic is administered as a single infusion therapy. The patient's own white blood cells are extracted from the blood, genetically modified in the laboratory and given back to those affected.